HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Masking 'Excessive' Microorganisms In Evanhealy Cosmetics From FDA

This article was originally published in The Rose Sheet

Executive Summary

Listings for more thazn 27,000 Plant Devas' evanhealy products are included in the latest update to FDA's database of regulated-product recalls that haven started by marketers or manufacturers and assigned a classification of urgency level, posted March 21.

You may also be interested in...



Senate Health Committee Releases Cosmetics Reform Discussion Draft

The committee's discussion draft of cosmetics reform legislation combines elements of the proposed Personal Care Products Safety Act and FDA Cosmetic Safety and Modernization Act, but most closely aligns with the former. NGOs likely will be pleased; small businesses, perhaps not so much

Honest Recalls Baby Powder Due To Possible Contamination

The Honest Company recalls all lots of its Organic Baby Powder following routine testing that indicated potential contamination with unsavory microorganisms. FDA scrutiny could follow.

No Change To US FDA’s Risk-Based Homeopathic Enforcement From Its OTC Monograph Overhaul

Final guidance presents same descriptions of six "categories of homeopathic drug products ... potentially posing higher risks to public health” agency stated in 2019 revised draft. Agency adds reference to monograph reform in explanation of how homeopathics aren't GRASE.  

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS121528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel